Form 4: Heron Therapeutics COO Receives Equity Awards

Heron Therapeutics' Chief Operating Officer, Mark Earl Hensley, was granted 188,315 Restricted Stock Units and 188,314 Performance Stock Units.

Summary

• Mark Earl Hensley, Chief Operating Officer of HERON THERAPEUTICS, INC. (HRTX), was granted equity awards on January 30, 2026.
• The grant included 188,315 Restricted Stock Units (RSUs) which convert into common stock on a one-for-one basis.
• The RSUs vest in 16 equal quarterly installments, beginning one quarter after the grant date.
• Additionally, 188,314 Performance Stock Units (PSUs) were granted, also converting into common stock on a one-for-one basis.
• The PSUs vest in 16 equal quarterly installments, starting one quarter after the grant date, subject to a milestone-based vesting condition.
• The PSU vesting is contingent on achieving a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the Issuer's Form 10-K.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development as it aligns executive incentives with shareholder value through both time-based and performance-based equity awards, which is a standard and generally beneficial corporate governance practice.

Positives

• The equity grants align the Chief Operating Officer's interests with those of shareholders, promoting long-term value creation.
• The inclusion of Performance Stock Units (PSUs) ties a significant portion of executive compensation directly to the company's financial performance, specifically net product sales revenue.

Risks

• The vesting of Performance Stock Units (PSUs) is subject to the satisfaction of a net product sales revenue target for the fiscal year ending December 31, 2026. Failure to meet this target could result in a lower percentage of PSUs vesting for the reporting person.

Future Outlook

The grants of Restricted Stock Units and Performance Stock Units establish future vesting schedules extending over 16 quarterly installments. The full realization of Performance Stock Units is contingent upon achieving a specified net product sales revenue target for the fiscal year ending December 31, 2026.

Industry Context

StockSavvy.ai notes that equity grants, particularly those combining time-based and performance-based components, are a standard practice in the biotechnology and pharmaceutical industry. This structure is designed to incentivize executive performance, align management's long-term interests with shareholder value, and retain key talent.

Comparison to Industry Standards

• Equity compensation packages for executives in the biotech sector commonly include a mix of time-based and performance-based awards. For instance, companies like Amgen Inc. (AMGN) and Gilead Sciences, Inc. (GILD) frequently utilize similar structures to motivate their leadership.
• The 16-quarter (four-year) vesting schedule for both RSUs and PSUs is consistent with typical long-term incentive plans seen across the industry, aiming to foster sustained performance rather than short-term gains.
• Tying PSU vesting to net product sales revenue targets is a common performance metric in the pharmaceutical industry, directly linking executive compensation to commercial success and market penetration, similar to practices at companies developing new therapies.

Related Party Transactions

• The grant of Restricted Stock Units and Performance Stock Units to Mark Earl Hensley, the Chief Operating Officer, constitutes an executive compensation transaction, which is a form of related party dealing.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value.
• Employees (specifically the COO): Direct benefit through potential future equity ownership, contingent on time-based vesting and company performance.

Next Steps

• The Restricted Stock Units (RSUs) will vest in 16 equal quarterly installments beginning one quarter after January 30, 2026.
• The Performance Stock Units (PSUs) will vest in 16 equal quarterly installments beginning one quarter after January 30, 2026, subject to the achievement of the net product sales revenue target for the fiscal year ending December 31, 2026.

Key Dates

Keywords

Heron Therapeutics, HRTX, Mark Earl Hensley, Chief Operating Officer, Restricted Stock Units, RSUs, Performance Stock Units, PSUs, equity grant, executive compensation, insider transaction, Form 4